Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model

Radiotherapy and Oncology

Volumn 116, Issue 3, 2015, Pages 438-442

  Rekers, Nicolle H ^a   Zegers, Catharina M L ^a   Yaromina, Ala ^a   Lieuwes, Natasja G ^a   Biemans, Rianne ^a   Senden Gijsbers, Birgit L M G ^a   Losen, Mario ^b   Van Limbergen, Evert J ^a   Germeraad, Wilfred T V ^a   Neri, Dario ^c   Dubois, Ludwig ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ETH ZURICH   (Switzerland)

Author keywords

Cancer; ED B; F9; Immunotherapy; MHCI

Indexed keywords

DARLEUKIN; ANTINEOPLASTIC AGENT; FIBRONECTIN; FN1 PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; HYBRID PROTEIN; L19-IL2 IMMUNOCYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; SYSTEMIC THERAPY; TERATOCARCINOMA; THERAPY EFFECT; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION; IMMUNOLOGY; INBRED MOUSE STRAIN; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; RADIOIMMUNOTHERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FIBRONECTINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; MICE; MICE, INBRED STRAINS; NEOPLASMS; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS;

EID: 84944167446     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.06.019     Document Type: Conference Paper

References (18)

1. J.C. Becker, J.D. Pancook, S.D. Gillies, K. Furukawa, and R.A. Reisfeld T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy J Exp Med 183 1996 2361 2366
2. B. Carnemolla, L. Borsi, E. Balza, and et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix Blood 99 2002 1659 1665
3. S. Demaria, and S.C. Formenti Radiotherapy effects on anti-tumor immunity: implications for cancer treatment Front Oncol 3 2013 128
4. S.C. Formenti, and S. Demaria Combining radiotherapy and cancer immunotherapy: a paradigm shift J Natl Cancer Inst 105 2013 256 265
5. K.L. Gutbrodt, G. Casi, and D. Neri Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice Mol Cancer Ther 13 2014 1772 1776
6. K.L. Gutbrodt, C. Schliemann, and L. Giovannoni Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia Sci Transl Med 5 2013 201ra118
7. F.H. Igney, and P.H. Krammer Immune escape of tumors: apoptosis resistance and tumor counterattack J Leukoc Biol 71 2002 907 920
8. T. List, and D. Neri Immunocytokines: a review of molecules in clinical development for cancer therapy Clin Pharmacol 5 2013 29 45
9. H.N. Lode, R. Xiang, T. Dreier, N.M. Varki, S.D. Gillies, and R.A. Reisfeld Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy Blood 91 1998 1706 1715
10. R. Medzhitov, and C.A. Janeway Jr. Decoding the patterns of self and nonself by the innate immune system Science 296 2002 298 300
11. A. Menrad, and H.D. Menssen ED-B fibronectin as a target for antibody-based cancer treatments Expert Opin Ther Targets 9 2005 491 500
12. L. Milas, K.A. Mason, H. Ariga, and et al. CpG oligodeoxynucleotide enhances tumor response to radiation Cancer Res 64 2004 5074 5077
13. M. Moschetta, F. Pretto, A. Berndt, and et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts Cancer Res 72 2012 1814 1824
14. N.H. Rekers, E.G. Troost, C.M. Zegers, W.T. Germeraad, L.J. Dubois, and P. Lambin Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives Cancer Radiother 18 2014 391 395
15. M.M. van den Heuvel, M. Verheij, R. Boshuizen, and et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy J Transl Med 13 2015 32
16. R.E. Vatner, B.T. Cooper, C. Vanpouille-Box, S. Demaria, and S.C. Formenti Combinations of immunotherapy and radiation in cancer therapy Front Oncol 4 2014 325
17. R. Xiang, H.N. Lode, C.S. Dolman, and et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy Cancer Res 57 1997 4948 4955
18. C.M. Zegers, N.H. Rekers, D.H. Quaden, and et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects Clin Cancer Res 21 2015 1151 1160